← SynDRA
ETODOLAC
SynDRA canonical compound SYN0001234 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PTGS2 |
|---|
| Mechanism of action | Cyclooxygenase inhibitor |
|---|
| Indication | osteoarthritis | rheumatoid arthritis |
|---|
| Disease area | rheumatology |
|---|
All known targets
Mechanisms of action (all sources)
- Cyclooxygenase inhibitor
- PTGS2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- DRD2
- ACHE
- MAOA
- NPY1R
- NFKB1
- NFE2L2
- MMP9
- MMP1
- MLNR
- MDH1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- LCK
- GHSR
- KDR
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- HDAC6
- NPY2R
- NR1I2
- NR3C1
- SLC22A6
- USP1
- UGT1A9
- TSHR
- TBXAS1
- TBXA2R
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT2A
- CP2C9
- CP2CJ
- CP2D6
- KCMB1
- MDR1
- NF2L2
Drug classes
- Cyclooxygenase Inhibitors
- Nonsteroidal Anti-inflammatory Drug
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Cyclooxygenase 2 Inhibitors
- Enzyme Inhibitors
- Peripheral Nervous System Agents
- Sensory System Agents
ATC classes
- M01A · ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Cross-references
Synonyms
- LODINE
- LODINE XL
- Lodine
- etodine
- etodolic acid
- hypen
- Etodolic acid
- Etodolaco
- (rs)-etodolic acid
- Eccoxolac
- Edolan
- Flancox
- Lodin xl
- Napilac
- Tedolan
- Ultradol
- Zedolac
- AY-24,236
- AY-24-236
- AY-24236
- NIH-9918
- NSC-282126
- Ebretin
- Etolyn
- Etopan xl
- Lodine sr
- Lodine xl
- Ramodar
- Lodine XL
- Etodolacum
- Etodolacum [INN-Latin]
- Etodolaco [INN-Spanish]
- CCRIS 3923
- CHEMBL622
- NSC 282126
- etodolac (ep monograph)
- AY 24236
Reported adverse events
- Alopecia
- Angioedema
- Anxiety
- Arrhythmia
- Asthenia
- Asthma
- Bronchitis
- Chills
- Conjunctivitis
- Cyst
- Cystitis
- Dyspepsia
Look up ETODOLAC in the interactive SynDRA portal →